A Statement of Changes in Beneficial Ownership was filed on September 21, 2026, disclosing that Edward Neugeboren, a director at Grace Therapeutics, Inc. (NASDAQ:GRCE), acquired a stock option grant dated September 17, 2026.

Key Highlights

  • Reporting person: Edward Neugeboren, identified as a Director of Grace Therapeutics, Inc.
  • Security acquired: A Stock Option (Right to Buy) covering 12,200 shares of Common Stock, acquired on September 17, 2026.
  • Exercise price: $2.13 per share, with an expiration date of September 16, 2036.
  • Price paid: $0 at the time of the grant, according to the filing.
  • Vesting schedule: 50% vests on the grant date; the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to continuous service.
  • Resulting ownership: 12,200 derivative securities beneficially owned following the reported transaction, held directly.

Director Option Grant Details at Grace Therapeutics

According to the filing, Edward Neugeboren, serving as a Director at Grace Therapeutics, Inc., a company incorporated and based in Princeton, New Jersey, received a stock option grant on September 17, 2026. The transaction was recorded under Table II (Derivative Securities) with transaction code "A," indicating an acquisition. The option carries an exercise price of $2.13 per share and grants the right to purchase up to 12,200 shares of Common Stock. The option was acquired at a price of $0, as stated in the filing.

The filing's Explanation of Responses notes that "50% of this option vests on the date of grant and the remaining 50% vests in substantially equal monthly installments over a 12-month period, subject to the Reporting Person's continuous service as of each vesting date." Following this transaction, Neugeboren's total beneficial ownership of derivative securities stands at 12,200, held in direct form. The filing was signed by Robert DelAversano as attorney-in-fact for Edward Neugeboren and submitted on September 21, 2026.

What Was Disclosed

The filing disclosed that Director Edward Neugeboren of Grace Therapeutics, Inc. (NASDAQ:GRCE) acquired a stock option for 12,200 shares of Common Stock at an exercise price of $2.13 per share, granted September 17, 2026, with a split vesting schedule over 12 months.